The Latest Breaking News from BristolMyers

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

"Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population," Bristol Myers said.

"Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population," Bristol Myers said.

Solid cancer and blood clot treatment sales, as well as a smaller-than-forecast decline for Revlimid, helped deliver a top and bottom line beat for drugmaker Bristol Myers.

“With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile," said Bristol Myers CEO Giovanni Caforio.